Burden of Disease Analysis
Quantifying Disease Impact for Evidence-Based Decision-Making
Burden of Disease Analysis
Burden of Disease (BoD) Analysis is a comprehensive epidemiological assessment used to quantify the impact of diseases and health conditions on populations. It integrates mortality, morbidity, disability, and healthcare resource utilization data to provide insights for public health policies, healthcare resource allocation, market access strategies, and Health Technology Assessments (HTA).
At Clievi, we offer robust, data-driven Burden of Disease Analysis services, leveraging real-world evidence (RWE), epidemiological models, and health economic methodologies to assess the global and regional impact of diseases. Our services support pharmaceutical companies, healthcare policymakers, payers, and regulatory bodies in making informed decisions.
Our Burden of Disease Analysis Services
1. Epidemiological Assessment & Disease Prevalence Estimation
A precise understanding of disease prevalence, incidence, and risk factors is crucial for evaluating disease burden. We provide:
- Prevalence & Incidence Estimation – Using real-world data (RWD), registry databases, and peer-reviewed literature to estimate disease frequency.
- Risk Factor Analysis – Assessing modifiable and non-modifiable risk factors contributing to disease progression.
- Age-Standardized & Gender-Stratified Disease Estimates – Ensuring demographic-specific insights for targeted interventions.
- Global & Regional Disease Burden Mapping – Using geospatial and predictive analytics to analyze disease distribution.
2. Disability-Adjusted Life Years (DALYs) & Quality-Adjusted Life Years (QALYs) Calculation
Burden of Disease is often expressed in DALYs and QALYs, which measure the impact of diseases in terms of premature mortality and disability.
a) Disability-Adjusted Life Years (DALYs)
- A composite measure combining Years of Life Lost (YLL) due to premature mortality and Years Lived with Disability (YLD).
- Utilized in public health decision-making, cost-effectiveness analysis, and HTA submissions.
b) Quality-Adjusted Life Years (QALYs)
- Measures disease impact on quality of life using patient-reported outcome measures (PROMs).
- Applied in economic evaluations, cost-utility analyses, and pharmaceutical reimbursement assessments.
We use Global Burden of Disease (GBD) study methodologies, integrating WHO, IHME, and national healthcare data sources for accuracy.
3. Economic Burden & Healthcare Cost Analysis
Understanding the direct and indirect costs associated with diseases is critical for pharmaceutical pricing, reimbursement strategies, and healthcare policy-making. Our economic burden assessments include:
- Direct Medical Costs – Estimating hospitalization, medication, diagnostics, and treatment costs.
- Indirect Costs – Evaluating productivity losses, absenteeism, and informal caregiving burdens.
- Budget Impact Analysis (BIA) – Forecasting healthcare expenditure trends under different intervention scenarios.
- Cost-of-Illness (COI) Studies – Comprehensive evaluations of financial burdens on healthcare systems and society.
We integrate claims databases, electronic health records (EHRs), national health expenditure data, and real-world evidence (RWE) for precise economic modeling.
4. Comparative Effectiveness & Treatment Burden Analysis
- Comparative Burden Assessment – Benchmarking disease burden across geographical regions, healthcare systems, and treatment modalities.
- Impact of New Interventions – Evaluating how novel therapies reduce disease burden compared to standard-of-care treatments.
- Unmet Medical Needs Identification – Highlighting treatment gaps and areas for future pharmaceutical innovation.
We employ advanced modeling techniques, including Markov models, microsimulation, and Bayesian network meta-analyses, to assess treatment impacts.
5. Health Technology Assessment (HTA) & Payer Evidence Support
Our Burden of Disease Analysis is structured to align with global HTA frameworks for market access, pricing, and reimbursement submissions:
- NICE (UK) – Cost-effectiveness and comparative burden assessments.
- CADTH (Canada) – Epidemiological modeling for pharmaceutical evaluations.
- ICER (US) – Burden of disease estimations for drug value assessments.
- G-BA & IQWiG (Germany) – Supporting pricing and reimbursement negotiations.
- PBAC (Australia) – Economic modeling and cost-burden analysis.
We ensure that our BoD reports meet the evidence expectations of regulators, payers, and reimbursement agencies.
Why Choose Clievi for Burden of Disease Analysis?
- Expert-Led Epidemiological Modeling – Our team comprises biostatisticians, epidemiologists, and HEOR specialists.
- Robust Data Analytics & Evidence Synthesis – We use RWE, meta-analysis, and predictive modeling techniques for data-driven insights.
- Regulatory & HTA Compliance – Adhering to GBD methodologies, PRISMA, NICE, ISPOR, and CHEERS guidelines.
- Advanced Statistical Tools – Utilizing TreeAge Pro, STATA, R, WinBUGS, and Excel-based decision models.
- Customizable BoD Reports – Tailored for pharmaceutical, biotechnology, medical device, and policy organizations.
Deliverables of Our Burden of Disease Analysis Services
- Burden of Disease Report – Comprehensive synthesis of epidemiological and economic disease burden data.
- DALY & QALY Calculations – Structured models with detailed health outcome measures.
- Cost-of-Illness Analysis – Breakdown of direct and indirect healthcare costs.
- Comparative Burden Assessments – Global and regional burden trends for disease prioritization.
- HTA & Payer Submission Dossiers – Evidence-based reports for market access and reimbursement approvals.
Industries We Serve
- Pharmaceutical & Biotechnology Companies – Supporting drug development, market access, and value demonstration.
- Health Technology Assessment (HTA) Bodies – Providing evidence-based burden evaluations.
- Healthcare Payers & Policy Makers – Informing reimbursement decisions and healthcare prioritization.
- Medical Device & Digital Health Firms – Assessing the impact of medical innovations on disease burden.
- Academia & Research Institutions – Conducting epidemiological and economic burden studies.
Contact Us
Ready to leverage data-driven Burden of Disease Analysis for evidence-based decision-making?
Email:
Website: www.clievi.com